Benzinga | Mar 17, 2021 07:14AM EDT

RBC Capital Initiates Coverage On Avid Bioservices with Outperform Rating, Announces Price Target of $21

RBC Capital analyst Sean Dodge initiates coverage on Avid Bioservices (NASDAQ:CDMO) with a Outperform rating and announces Price Target of $21.